[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 962 Introduced in Senate (IS)]
<DOC>
117th CONGRESS
1st Session
S. 962
To prioritize funding for an expanded and sustained national investment
in biomedical research.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
March 24, 2021
Mr. Durbin (for himself, Mr. Van Hollen, Ms. Baldwin, Mr. Brown, Mr.
Cardin, Mr. Blumenthal, and Ms. Klobuchar) introduced the following
bill; which was read twice and referred to the Committee on
Appropriations
_______________________________________________________________________
A BILL
To prioritize funding for an expanded and sustained national investment
in biomedical research.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``American Cures Act''.
SEC. 2. APPROPRIATIONS FOR INNOVATION.
(a) In General.--There are hereby authorized to be appropriated,
and appropriated, out of any monies in the Treasury not otherwise
appropriated, the following:
(1) National institutes of health.--For the National
Institutes of Health at the Department of Health and Human
Services--
(A) for fiscal year 2022, $45,903,000,000;
(B) for fiscal year 2023, $49,116,000,000;
(C) for fiscal year 2024, $52,554,000,000;
(D) for fiscal year 2025, $56,233,000,000;
(E) for fiscal year 2026, $60,169,000,000;
(F) for fiscal year 2027, $64,380,000,000;
(G) for fiscal year 2028, $68,890,000,000;
(H) for fiscal year 2029, $73,710,000,000;
(I) for fiscal year 2030, $78,870,000,000;
(J) for fiscal year 2031, $84,390,000,000; and
(K) for fiscal year 2032 and each fiscal year
thereafter, the amount appropriated under this
paragraph for the previous fiscal year, increased by
the percentage increase (if any), during the previous
fiscal year, in the Consumer Price Index for all urban
consumers published by the Bureau of Labor Statistics.
(2) Centers for disease control and prevention.--For the
Centers for Disease Control and Prevention at the Department of
Health and Human Services--
(A) for fiscal year 2022, $8,453,000,000;
(B) for fiscal year 2023, $9,044,000,000;
(C) for fiscal year 2024, $9,667,000,000;
(D) for fiscal year 2025, $10,354,000,000;
(E) for fiscal year 2026, $11,079,000,000;
(F) for fiscal year 2027, $11,850,000,000;
(G) for fiscal year 2028, $12,680,000,000;
(H) for fiscal year 2029, $13,570,000,000;
(I) for fiscal year 2030, $14,520,000,000;
(J) for fiscal year 2031, $15,540,000,000; and
(K) for fiscal year 2032 and each fiscal year
thereafter, the amount appropriated under this
paragraph for the previous fiscal year, increased by
the percentage increase (if any), during the previous
fiscal year, in the Consumer Price Index for all urban
consumers published by the Bureau of Labor Statistics.
(3) Research, development, test, and evaluation program of
the department of defense health program.--For the research,
development, test, and evaluation program of the Department of
Defense health program--
(A) for fiscal year 2022, $2,890,000,000;
(B) for fiscal year 2023, $3,090,000,000;
(C) for fiscal year 2024, $3,310,000,000;
(D) for fiscal year 2025, $3,540,000,000;
(E) for fiscal year 2026, $3,790,000,000;
(F) for fiscal year 2027, $4,060,000,000;
(G) for fiscal year 2028, $4,340,000,000;
(H) for fiscal year 2029, $4,640,000,000;
(I) for fiscal year 2030, $4,970,000,000;
(J) for fiscal year 2031, $5,320,000,000; and
(K) for fiscal year 2032 and each fiscal year
thereafter, the amount appropriated under this
paragraph for the previous fiscal year, increased by
the percentage increase (if any), during the previous
fiscal year, in the Consumer Price Index for all urban
consumers published by the Bureau of Labor Statistics.
(4) Medical and prosthetics research program of the
department of veterans affairs.--For the medical and
prosthetics research program of the Department of Veterans
Affairs--
(A) for fiscal year 2022, $872,000,000;
(B) for fiscal year 2023, $933,000,000;
(C) for fiscal year 2024, $998,000,000;
(D) for fiscal year 2025, $1,070,000,000;
(E) for fiscal year 2026, $1,140,000,000;
(F) for fiscal year 2027, $1,220,000,000;
(G) for fiscal year 2028, $1,310,000,000;
(H) for fiscal year 2029, $1,400,000,000;
(I) for fiscal year 2030, $1,500,000,000;
(J) for fiscal year 2031, $1,600,000,000; and
(K) for fiscal year 2032 and each fiscal year
thereafter, the amount appropriated under this
paragraph for the previous fiscal year, increased by
the percentage increase (if any), during the previous
fiscal year, in the Consumer Price Index for all urban
consumers published by the Bureau of Labor Statistics.
(b) Availability.--Amounts appropriated under subsection (a) shall
remain available until expended.
(c) Definitions.--In this section:
(1) Centers for disease control and prevention.--The term
``Centers for Disease Control and Prevention'' means the
appropriations accounts that support the various institutes,
offices, and centers that make up the Centers for Disease
Control and Prevention.
(2) Research, development, test, and evaluation program of
the department of defense health program.--The term ``research,
development, test, and evaluation program of the Department of
Defense health program'' means the appropriations accounts that
support the various institutes, offices, and centers that make
up the research, development, test, and evaluation program of
the Department of Defense health program.
(3) Medical and prosthetics research program of the
department of veterans affairs.--The term ``medical and
prosthetics research program of the Department of Veterans
Affairs'' means the appropriations accounts that support the
various institutes, offices, and centers that make up the
medical and prosthetics research program of the Department of
Veterans Affairs.
(4) National institutes of health.--The term ``National
Institutes of Health'' means the appropriations accounts that
support the various institutes, offices, and centers that make
up the National Institutes of Health.
(d) Exemption of Certain Appropriations From Sequestration.--
(1) In general.--Section 255(g)(1)(A) of the Balanced
Budget and Emergency Deficit Control Act (2 U.S.C.
905(g)(1)(A)) is amended by inserting after ``Advances to the
Unemployment Trust Fund and Other Funds (16-0327-0-1-600).''
the following:
``Appropriations under the American Cures
Act.''.
(2) Applicability.--The amendment made by this section
shall apply to any sequestration order issued under the
Balanced Budget and Emergency Deficit Control Act of 1985 (2
U.S.C. 900 et seq.) on or after the date of enactment of this
Act.
(e) Budgetary Effects.--
(1) Statutory paygo scorecards.--The budgetary effects of
this section shall not be entered on either PAYGO scorecard
maintained pursuant to section 4(d) of the Statutory Pay-As-
You-Go Act of 2010 (2 U.S.C. 933(d)).
(2) Senate paygo scorecards.--The budgetary effects of this
section shall not be entered on any PAYGO scorecard maintained
for purposes of section 4106 of H. Con. Res. 71 (115th
Congress).
<all>